Choreo LLC Buys Shares of 32,515 Dynavax Technologies Co. (NASDAQ:DVAX)

Choreo LLC purchased a new position in shares of Dynavax Technologies Co. (NASDAQ:DVAX) during the 2nd quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor purchased 32,515 shares of the biopharmaceutical company’s stock, valued at approximately $363,000.

Other hedge funds and other institutional investors have also modified their holdings of the company. Duality Advisers LP acquired a new stake in shares of Dynavax Technologies in the first quarter worth about $227,000. Natixis Advisors L.P. boosted its position in Dynavax Technologies by 10.5% during the fourth quarter. Natixis Advisors L.P. now owns 19,058 shares of the biopharmaceutical company’s stock worth $266,000 after purchasing an additional 1,804 shares during the period. Boston Partners bought a new stake in Dynavax Technologies during the first quarter worth approximately $292,000. China Universal Asset Management Co. Ltd. raised its position in shares of Dynavax Technologies by 67.8% in the first quarter. China Universal Asset Management Co. Ltd. now owns 25,099 shares of the biopharmaceutical company’s stock valued at $311,000 after purchasing an additional 10,143 shares during the period. Finally, Diversified Trust Co raised its position in shares of Dynavax Technologies by 3.2% in the first quarter. Diversified Trust Co now owns 29,548 shares of the biopharmaceutical company’s stock valued at $367,000 after purchasing an additional 925 shares during the period. Institutional investors own 96.96% of the company’s stock.

Analysts Set New Price Targets

DVAX has been the topic of several recent analyst reports. HC Wainwright reiterated a “buy” rating and issued a $29.00 target price on shares of Dynavax Technologies in a report on Wednesday, August 7th. The Goldman Sachs Group cut their price objective on Dynavax Technologies from $20.00 to $15.00 and set a “neutral” rating for the company in a research report on Thursday, August 8th. Finally, StockNews.com lowered Dynavax Technologies from a “buy” rating to a “hold” rating in a report on Tuesday, May 28th. Two equities research analysts have rated the stock with a hold rating and three have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $23.67.

Dynavax Technologies Stock Down 0.2 %

Shares of DVAX opened at $11.15 on Tuesday. Dynavax Technologies Co. has a 52 week low of $9.74 and a 52 week high of $15.15. The firm has a market capitalization of $1.46 billion, a P/E ratio of 185.83 and a beta of 1.37. The company has a 50-day simple moving average of $11.00 and a 200-day simple moving average of $11.50. The company has a debt-to-equity ratio of 0.35, a quick ratio of 13.18 and a current ratio of 14.18.

Dynavax Technologies (NASDAQ:DVAX) last announced its quarterly earnings data on Tuesday, August 6th. The biopharmaceutical company reported $0.08 EPS for the quarter, topping analysts’ consensus estimates of $0.06 by $0.02. The company had revenue of $73.80 million during the quarter, compared to the consensus estimate of $76.92 million. Dynavax Technologies had a return on equity of 2.76% and a net margin of 6.88%. During the same quarter last year, the company earned $0.03 EPS. On average, equities research analysts expect that Dynavax Technologies Co. will post 0.16 earnings per share for the current year.

Dynavax Technologies Profile

Dynavax Technologies Corporation, a commercial stage biopharmaceutical company, focuses on developing and commercializing vaccines in the United States. It markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe.